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Abstract
Background: Advanced pancreatic cancer, in addition to its high mortality, is characterized by one
of the highest rates of venous thromboembolic events (VTE) as compared to other types of cancer.
Enoxaparin, a low molecular weight heparin (LMWH), has proven to be effective for the prevention
and treatment of VTE in surgical and general medical patients. Results of some small studies suggest
that this benefit might extend to patients with cancer, however, enoxaparin is not currently
indicated for this use. This phase IIb study was designed to analyze the efficacy of enoxaparin in
patients with locally advanced or metastatic pancreatic cancer undergoing systemic chemotherapy.
Methods: The aim of this prospective multicenter trial is to compare concomitant treatment with
enoxaparin to no anticoagulation in 540 patients. Primary endpoint is the incidence of clinically
relevant VTE (symptomatic deep venous thrombosis (DVT) of the leg and/or pelvic and/or
pulmonary embolism (PE)) within the first 3 months. Secondary endpoints include the incidence of
symptomatic and asymptomatic VTE after 6, 9 and 12 months as well as remission at 3, 6, 9 and 12
months, overall survival and bleeding. Trial registration: isrctn.org identifier CCT-NAPN-16752,
controlled-trials.com identifier: ISRCTN02140505.
Results: An interim analysis for safety performed after inclusion of 152 patients revealed no
increased risk of bleeding (5 pts vs. 6 pts, Chi2: 0.763).
Conclusion: PROSPECT is a pivotal study in elucidating the role of low molecular weight heparins
in advanced pancreatic cancer. Its results will lead to a new understanding of the role of heparins
in the prevention of venous thromboembolism and of their effect on survival, remission rates and
toxicity of chemotherapeutic regimens.
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Background
Pancreatic cancer is among the most common malignan-
cies in the world with about 232,000 new cases every year
[1]. Due to its aggressive nature this illness accounts for
around 32,000 deaths per year in the United States [2],
and around 47,000 in Western Europe [3]. The median
survival time is 6–10 months with locally advanced dis-
ease and 3 to 6 months in patients with metastases. With-
out any specific anticancer therapy the median overall
survival is between 2 to 4 months.
In addition to the poor over-all prognosis the course of
the disease is often complicated by thromboembolic
events. Lower-extremity deep venous thrombosis, throm-
bophlebitis migrans, and pulmonary embolism are
among the well-known presentations in pancreatic can-
cer. Further manifestations also include disseminated
intravascular coagulation, splenic vein thrombosis, portal
or superior mesenteric vein thrombosis, and spontaneous
arterial thromboembolism, extremity ischemia, and
mesenteric or iliofemoral occlusion [4-7].
The first report describing the relationship between pan-
creatic cancer and thrombosis was published in 1938,
documenting a 60% prevalence of venous thrombosis in
various locations upon autopsy compared with 15–25%
in other malignancies [8]. This makes pancreatic cancer
the tumour entity with the highest VTE rates. Since then,
further studies have confirmed the association of pancre-
atic adenocarcinoma with VTE reporting prevalence rates
of 5 to 60% [9-12]. In a recent cohort study in 202
patients with pancreatic cancer (based on histological and
cytological examinations or ultrasound and CT) the inci-
dence of VTE was 108.3 per 1,000 patient-years (10.8%)
resulting in a 58.6-fold increase in relative risk as com-
pared with an age- and sex-adjusted general population
[13]. Patients treated with chemotherapy have further a
4.8-fold increased risk for VTE [14-16], whereas the risk
increase is at worst moderate with radiotherapy [17]. In a
study conducted in 7,000 patients with different cancers,
Sorensen and colleagues found that 12% of patients with
and 36% of patients without VTE were alive at one year
[18], a result documenting the negative prognostic impli-
cation of clinical VTE in cancer patients. The prothrombo-
genic effects of malignant disease have been extensively
studied and revealed direct and indirect activation of
coagulation, inhibition of fibrinolysis, enhancement of
adhesion of blood cells and/or the initiation of an inflam-
matory state [19,20] (Figure 1). For an excellent overview
see Nakchbandi and Löhr [21].
Following the initial observation that cancer patients tend
to develop venous thrombosis different anticoagulants
were tested to decrease the risk of VTE. Three studies
showed the superiority of low molecular weight heparins
in terms of a favourable benefit risk ratio in this indication
[22-24] in comparison to oral anticoagulants. The inci-
dence of bleeding so far described for cancer patients
Initiation of the coagulation and angiogenic cascades by pancreatic tumour cells (modified from [61]) Figure 1
Initiation of the coagulation and angiogenic cascades by pancreatic tumour cells (modified from [61]). Figure leg-
end text: TF, tissue factor; VEGF, vascular endothelial growth factor; PAR, protease-activated receptor; TSP, thrombospondin; 
HGBF2, heparin-binding growth factor 2 (previously called fibroblast growth factor 2 [FGF-2]).BMC Cancer 2008, 8:361 http://www.biomedcentral.com/1471-2407/8/361
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receiving oral anticoagulant treatment for VTE is markedly
lower than the high incidence of recurrent venous throm-
bosis in these cancer patients [25]. In retrospective meta-
analyses from randomized trials of VTE patients initially
treated with low molecular weight heparin (LMWH) it
was demonstrated that mortality after 3 months was up to
50% lower as compared to patients started on anticoagu-
lation with unfractionated heparin [26-29]; this beneficial
effect of LMWH on mortality nearly exclusively resulted
from the effect observed in cancer patients [26,28].
In addition to anticoagulation inhibiting VTE events there
is evidence that LMWH have additional pleitropic effects.
The low incidence of malignancies in patients using long-
term anticoagulant therapy raised the possibility of antin-
eoplastic activities of these drugs [26,28,30]. Also, dra-
matic tumour regression in some case reports and small
studies has suggested the potential for anti-cancer activity
of LMWH [26,28,31-33]. LMWH therefore may be
regarded not only as a suitable anticoagulant in cancer
patients with VTE but as also anti-cancer or anti-metastatic
therapeutic principle.
Recent guidelines of the American College of Chest Physi-
cians (ACCP) recommend the use of LMWH for anticoag-
ulation in patients with cancer-induced thrombosis [34].
The LMWH enoxaparin, based on the ENOXACAN II
study [35], is effective for the prolonged primary preven-
tion of thrombosis after surgery for abdominal or pelvic
cancer and has been recommended for surgical patients
with cancer at high risk by the recently published guide-
lines of the International Union of Angiology [36].
Therapeutic implications for patients with pancreatic 
cancer
Given the high incidence of thromboses effective antico-
agulant therapy may be warranted in patients with pancre-
atic cancer [13]. A recent small phase II trial suggested an
improved survival by the addition of LMWH to chemo-
therapy [33]. Icli and colleagues aimed to assess the effi-
cacy of the addition of LMWH to gemcitabine (GEM) plus
cisplatinum (CDDP) combination chemotherapy on sur-
vival. 69 consecutive patients with advanced pancreatic
cancer were treated with GEM (800 mg/m2, day 1, day 8)
plus CDDP (35 mg/m2, day 1, day 8) every 21 days +/-
LMWH (nadroparine calcium, 2,850 IU/day until disease
progression). Ten out of 35 patients in the LMWH group
and 10 out of 34 patients in the chemotherapy alone
group had primary inoperable locally advanced disease
and the rest of the patients had metastatic disease. Total
response rate was reported to be 58.8% (complete remis-
sion 11.7%) for the patients treated with LMWH and
12.1% (no complete remission) for those treated without
LMWH (P = 0.0001). The LMWH group had a better
median time to progression and survival when compared
to control group (7.3 vs. 4.0 months, P = 0.0001; 13.0 vs.
5.5 months, P = 0.0001). The toxicity was similar and
acceptable in both groups. The authors concluded that the
addition of LMWH to the GEM plus CDDP combination
significantly improved the response and survival in
patients with advanced pancreatic cancer and the current
schedule deserves to be tested in future clinical trials.
Rationale for PROSPECT
Based on these encouraging trial results of LMWH, the
aim of Prospective, Randomized trial Of Simultaneous
Pancreatic cancer treatment with Enoxaparin (PROS-
PECT) is to investigate the efficacy of low molecular
weight heparin (enoxaparin) for the prevention of venous
thromboembolism in patients with advanced localized or
metastasized pancreatic cancer as a primary endpoint.
Methods of the PROSPECT study
Design
The study is a prospective, open-label, randomised, mul-
ticenter and group-sequential phase IIb study in patients
with locally advanced or metastasized pancreatic cancer
who are treated with a palliative chemotherapy (stratified
for risk) using either gemcitabine alone or in combination
with cisplatin, 5-fluorouracil (5-FU) and folinic acid, both
with or without enoxaparin. It was registered with
isrctn.org (CCT-NAPN-16752) and controlled-trials.com
(ISRCTN02140505). Ethical approval was obtained of the
ethics committee of the Charite University Clinic Berlin.
Primary stratification takes place according to Karnofsky
performance status (KPS) and kidney function. Patients
with a KPS > 80% and normal kidney function (creatinine
plasma level < upper limit of normal) receive GFFC ther-
apy (gemcitabine 1 g/m2 (30 min), 5-FU 750 mg/m2 (24
h), and folinic acid 200 mg/m2 (30 min), cisplatin 30 mg/
m2 (90 min)day 1, 8; q3w). After 12 weeks of initial GFFC
chemotherapy all patients with no cancer progression
receive standard therapy (gemcitabine 1 g/m2 (30 min),
d1, 8, 15; q4w). Patients with KPS < 80% and/or increased
creatinine plasma levels start with the standard therapy
(gemcitabine 1 g/m2 (30 min), day 1, 8, 15; q4w). Both
treatment groups were randomized to enoxaparin (1 mg/
kg BW qd for the first three months followed by 40 mg qd
for an additional three months) or to no anticoagulation.
For further details see figure 2.
Endpoints
The primary endpoint is the reduction of symptomatic
clinically relevant venous thromboembolic events in the
group treated with enoxaparin compared to no treatment
arm within 3 month. Clinically relevant thromboembolic
events are defined as symptomatic DVT of the leg and/or
pelvis and/or pulmonary embolism.BMC Cancer 2008, 8:361 http://www.biomedcentral.com/1471-2407/8/361
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Secondary endpoints include: 1) Incidence of sympto-
matic thromboembolic events within the first 6, 9 and 12
months; 2) Incidence of asymptomatic, subclinical deep
vein thrombosis during months 6, 9 and 12 determined
by compression ultrasound sonography; 3) Total survival,
rates of remission at 3, 6, 9 and 12 months, toxicity of the
therapeutic regimen, time to tumour regression and qual-
ity of life during chemotherapy with or without enoxa-
parin and the rate of major bleeding. Overall survival and
time to tumour progression will be analysed separately
following intention to treat and according to protocol
principles. A subgroup analysis of patients without any
thromboembolic events during the study will be per-
formed to explore possible pleitropic effects.
Study population
Inclusion criteria were the following: 1) Histologic or
cytologic confirmed pancreatic cancer stage IV; 2) No pre-
vious radio- or chemotherapy of the primary tumour or
the reference lesions; 3) KPS ≥ 60%; 4) Measurable
tumour lesion confirmed by computed tomography (CT)
or magnetic resonance tomography (MRT) within the last
14 days; 5) No DVT within the last 2 years, adequately
compliant patient and home residence within geographi-
cal proximity to the hospital which allows an adequate
follow-up; 6) Sufficient bone marrow function (leuko-
cytes ≥ 3.5 × 109/l, thrombocytes ≥ 100 × 109/l); 7) Writ-
ten informed consent; 8) Age ≥ 18 years, male and female
patients in childbearing age have to have an adequate con-
traception during and up to 6 months after the study.
Study design Figure 2
Study design. Figure legend text: KPS, Karnowsky Performance Status; Crea, Creatinine; ULN, upper limit of normal (> 1.1 
mg/dl for men and > 0.9 mg/dl for women); GFFC, combination of gemcitabine, 5-fluorouracil, folinic acid and cisplatin; GEM, 
gemcitabine monotherapy; PD, partial remission; CR, complete remission.
12 weeks / staging 12 weeks / staging
Gem mono ± LMWH
PD
Staging at least every 12 weeks
Randomization Randomization
Stratification Group A Group B
GFFC GFFC + LMWH GEM + LMWH GEM
KPS 60 – 70% or Crea > ULN KPS ≥ 80% and Crea ≤ ULN
DeathBMC Cancer 2008, 8:361 http://www.biomedcentral.com/1471-2407/8/361
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Exclusion criteria included the following: 1) Acute infec-
tion or pre-existing indication for anticoagulation. Bleed-
ing within the last 2 weeks or increased risk of bleeding
(severe impairment of coagulation, active stomach-gut
ulcers or surgery within the last 2 weeks); 2) Body weight
< 45 or > 100 kg; 3) Pregnancy/lactation or insufficient
contraception during study; 4) Psychiatric disease; 5)
Severe concomitant disease that is not compatible with a
participation in the study; 6) Hypersensitivity against one
of the drugs used or against structurally similar drugs; 7)
Patients with severely impaired renal function (creatinine
clearance < 30 ml/min).
Investigational plan
Therapy is continued until documented progression is
observed or as long the patient benefits from therapy. CT
or MRT is performed at least every 12 weeks or earlier in
case of suspected progression (figure 3).
Dose adjustment for enoxaparin is recommended in
patients with impaired kidney function and thrombocyto-
penia. Following the NCI-CTC (National Cancer Institute
Common Toxicity Criteria) a reduction of enoxaparin to
0.5 mg/kg is recommended in NCI stage II (thrombocytes
50.000 – 75.000/μl) until an increase in thrombocytes >
75.000/μl. Enoxaparin is to be interrupted in thrombocy-
topenia below 50.000/μl (NCI III).
To treat nausea and vomiting during the study, patients in
the GFFC group receive preventively tropisetrone (5 mg)
and dexamethasone (12 mg) for example and if necessary
additionally alizapride (100 mg) on days 0, 1, 2, 8, 9 and
10. For patients allocated to standard gemcitabine therapy
preventive alizapride 100 mg and dexamethasone 8 mg
were recommended. In case of any toxicity (> NCI grade II)
the dose is adjusted according to the protocol guidelines.
Concomitant therapy: It is recommended for patients with
Treatment pathway Figure 3
Treatment pathway. Figure legend text: GFFC, combination of gemcitabine, 5-fluorouracil, folinic acid and cisplatin; GEM, 
gemcitabine; CIS, cisplatin; FA, folinic acid; 5-FU, 5 fluorouracil; d, day.
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a haemoglobin level below 10.5 mg/dl to give 150 μg/
week darbopoetin alfa. Enteral or parenteral additional
nutrition, adequate pain-relief (NCI-scheme [37]) and
adequate vitamin supplementation is provided.
Statistical assumptions and timelines
A risk of symptomatic thromboembolism of 10% and an
absolute risk reduction of 7% under enoxaparin treatment
to 3% are assumed within the first 3 months. Enrolment
of 540 patients will provide an 80% power to verify this
difference.
After amendment 1 in June 2006, all patients without
symptomatic event of DVT or PE were to receive an ultra-
sound-based diagnostic of the legs every three months to
detect subclinical thrombosis. All subclinical or clinical
events of DVT/PE are documented centrally. The signifi-
cance of the events are evaluated by an independent
blinded "event review board". All patients will be evalu-
ated regarding the "intent to treat" and the "according to
protocol" analysis.
Interim analysis
According to protocol, an interim analysis for safety was
conducted when 152 patients were enrolled into the
PROSPECT trial. There was no difference in overall bleed-
ing as well as major bleedings between the two groups (5
pts vs. 6 pts, Chi2: 0.763). No heparin-induced thrombo-
cytopenia was observed.
Discussion
Besides the PROSPECT study, there are currently only
three registered ongoing trials investigating the role of
LMWH in patients with pancreatic cancer
(NCT00426127, NCT00031837 and NCT00312013) all
registered at clinicaltrials.gov the official NIH/FDA web-
site for study registration. NCT00426127 is a small non-
randomized, uncontrolled, open label efficacy study in 27
patients with advanced pancreatic cancer. Docetaxel and
liposomal doxorubicin chemotherapy is administered
together with enoxaparin. Primary outcome is tumour
response measured by CT scans after cycles 3 and 6. Sec-
ondary outcome is incidence of elevated D-Dimer meas-
ured by drawing D-Dimer levels every cycle. Safety and
effect of chemotherapy regimen on D-Dimer measured by
drawing D-Dimer levels every cycle are also investigated.
NCT00031837 is a randomized, multicentric active con-
trolled study comparing dalteparin to placebo in 400
patients with histologically or cytologically confirmed
pancreatic adenocarcinoma or poorly differentiated carci-
noma of the pancreas considered ineligible for curative
resection (unresectable or metastatic). Chemotherapy reg-
imen used is gemcitabine monotherapy. Primary or sec-
ondary endpoints have not been disclosed. Recruitment
started in October 2002 (first record received at clinicaltri-
als.gov). The trial is at present still active but not enrolling
(last update October 2008). NCT00312013  is  a  rand-
omized, open-label, uncontrolled, parallel assignment
safety/efficacy study in 500 patients with advanced malig-
nancies (including pancreatic cancer). Effects of
nadroparin in patients with lung, pancreas or prostate
cancer are investigated. Primary outcomes are death from
causes at study end (follow-up until at least 46 weeks after
randomization). Secondary outcome is time to tumour
progression. Recruitment started in March 2006 and is
still active but not recruiting (last update November
2008).
Rationale for the combination of gemcitabine, cisplatin, 5-
fluorouracil and folic acid
Most randomized trials of the last decade failed to demon-
strate a significant benefit from gemcitabine based combi-
nation therapies for pancreatic cancer. But sub-analyses
showed a survival benefit for more intensive therapies in
patients with good Karnofsky Performance Status [38,39].
Consistent with these results, we implemented a primary
stratification regarding to medical constitution. Data from
several phase II and randomised phase III studies, which
investigated a combination of gemcitabine and cisplatin
vs. gemcitabine monotherapy, suggested an increased
response of tumours to therapy (between 11 and 35%)
and a prolonged median survival (between 5.7 and 8.4
months) reaching significance in patients with good per-
formance status [38,40-47]. Pre-clinical data document
further the synergism between gemcitabine and 5-FU,
since both inhibit the de-novo synthesis of thymidinribo-
nucleotides [48]. The combination of gemcitabine and 5-
FU has furthermore been investigated in clinical trials,
amongst these data of our own group [49,50]. In a phase
I study we were able to demonstrate, that a combination
of gemcitabine (100 mg/m2), 5-FU (750 mg/m2) and foli-
nic acid (200 mg/m2) is an effective therapeutic regimen
with a low number of side effects resulting in remissions
and a median survival of more than 8 months in outpa-
tients [50]. In a recently published phase II study, El-Rayes
and colleagues treated 47 patients with advanced or
metastasised pancreatic cancer with a combination of
gemcitabine, cisplatin and 5-FU. Excellent tumour
response (26%) was achieved and the 1-year survival rate
for patients with metastases was 34% and the median
overall survival 8.6 months [51].
Actually, in a wide range of completed phase III studies,
there are only two trials presenting a significance improve-
ment in overall survival in patients with advanced or met-
astatic pancreatic carcinoma. One of them used the
combination of gemcitabine with capecitabine (5-FU pro-
drug) [52] the other highlights the superiority of gemcit-
abin in addition with erlotinib over single agentBMC Cancer 2008, 8:361 http://www.biomedcentral.com/1471-2407/8/361
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gemcitabine [53]. The clinical impact of these studies is
now under discussion.
Rationale for the choice of the anticoagulant
Recently, heparin and especially LMWH have been shown
to inhibit tumour growth and to increase the efficacy of
chemotherapy [54,55]. In comparison to unfractionated
heparin (UFH), LMWH has greater inhibitory activity
against growth factors, angiogenesis, and coagulation
activity [56]. In addition to the experimental tumour
models reporting tumour growth-inhibiting activity of
LMWH, there are some substantial tumour responses with
LMWH in a variety of cancers [31,32,57]. Along with the
endothelial cell-damaging effects of cisplatinum, the anti-
proliferative effect of heparins on endothelial cells could
be another explanation for the antitumour activity of the
current treatment regimen [58-60]. Finally enoxaparin is
recommended by the recently published IUA guidelines
for the prolonged prevention of thrombosis [36]. An
interims analysis of this pilot trial showed that enoxaparin
use (1 mg/kg BW for the first 3 months followed by 40 mg
for additional 3 months) was not associated with an
increase in overall and major bleeding as compared to
observation and recruitment has been resumed. This lack
of increased bleeding with LMWH in this patient popula-
tion treated with chemotherapy has also been observed
when compared to vitamin K antagonists [23,24].
Conclusion
PROSPECT is a pivotal study in elucidating the role of low
molecular weight heparins in advanced pancreatic cancer.
Its results will lead to a new understanding of the role of
heparins in the prevention of venous thromboembolism
and of their effect on survival, remission rates and toxicity
of chemotherapeutic regimens.
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